Peripheral Blood Stem Cell Mobilization by Chemotherapy With and Without Recombinant Human Granulocyte Colony-Stimulating Factor
- 1 January 1992
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy
- Vol. 1 (4) , 317-327
- https://doi.org/10.1089/scd.1.1992.1.317
Abstract
Chemotherapy can serve as a stimulus for mobilizing hematopoietic progenitor cells to the peripheral blood for harvest via leukapheresis. Mobilized peripheral blood stem cells (PBSC) support rapid hematologic reconstitution after bone marrow aplasia induced by intensive myelosuppressive treatments. Our purpose was to develop effective mobilization regimens allowing collection of large quantities of PBSC. We administered high-dose cyclophosphamide (HDC, 4 gm/m2) or cyclophosphamide (4 gm/m2) plus etoposide (600 mg/m2) (HDCE) in a nonrandomized, sequential fashion to 94 patients with breast cancer, lymphoma, and other malignancies with collection of PBSC via leukapheresis during white blood cell (WBC) recovery from nadir counts. Each apheresis product was analyzed for total nucleated cell number, granulocyte-macrophage colony-forming units (CFU-GM) and CD34+ cells. Twenty-four additional patients with comparable pretreatment characteristics received HDCE plus recombinant human granulocyte colony-stimulating factor (HDCE + G) after chemotherapy through the end of apheresis. Patients receiving HDC were matched for age, sex, and disease but were more heavily pretreated. HDCE was superior to HDC in mean daily CFU-GM and CD34+ yield (p < 0.05), even when groups were adjusted for performance status and amount of prior therapy. HDCE + G led to 3.7 times more CFU-GM and 4.7 times more CD34+ cells than HDCE. Target PBSC yield, defined as >20 x 104 CFU-GM/kg and >4 x 108 cells/kg, was achieved by 92% of HDCE + G patients after a median of three aphereses, 56% of HDCE patients after five aphereses, and 16% of HDC patients after six aphereses (p < 0.0001). Prior chemotherapy inversely correlated with the quantity of PBSC harvested regardless of regimen utilized. Our results demonstrate effective chemotherapy regimens for harvesting hematopoietic progenitors in a diverse patient population. HDCE + G produced the highest number of progenitors, suggesting that increasing dose intensity and adding rhG-CSF enhances mobilization. Correlation between cumulative CD34+ and CFU-GM allows real-time flow cytometric analysis of the number of aphereses required to harvest target numbers of PBSC.Keywords
This publication has 20 references indexed in Scilit:
- Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSFEuropean Journal of Cancer and Clinical Oncology, 1991
- Blood-derived haematopoietic cell transplants: blood to blood?The Lancet, 1991
- Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSFEuropean Journal of Cancer and Clinical Oncology, 1990
- Hematopoietic reconstitution using progenitors recovered from bloodTransfusion, 1989
- Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties.The Journal of Experimental Medicine, 1989
- The metabolic basis for combination chemotherapyPharmacology & Therapeutics, 1988
- CELL-DOSE EFFECT IN CIRCULATING STEM-CELL AUTOGRAFTINGThe Lancet, 1986
- Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes.Journal of Clinical Investigation, 1984
- High levels of circulating haemopoietic stem cells in very early remission from acute non‐lymphoblastic leukaemia and their collection and cryopreservationBritish Journal of Haematology, 1984
- Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancerCancer, 1975